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Chapter
Level of Antibody Response 
against Hepatitis B Virus after 
Vaccination and Seroprevalence 
of HBV in Children Addis Ababa, 
Ethiopia
Habtamu Biazin and Seifegebriel Teshome
Abstract
Approximately 2 billion people worldwide are infected with HBV and more 
than 240 million are chronic carriers. The World Health Organization officially 
launched the introduction of the hepatitis B vaccine for children in 1980. Since 
then, different countries have determined the level of response to the vaccine. Since 
the introduction of the vaccine in Ethiopia in 2007, there have been few studies 
evaluating the antibody response to the HBV vaccine. Therefore, the purpose of this 
study is to determine the HBV antibody response after hepatitis B vaccination and 
to evaluate the HBV seroprevalence of children in Addis Ababa, Ethiopia. A cross-
sectional study was conducted using a multistage probability sampling technique. 
Four hundred and fifty children between the ages of five and eight living in Addis 
Ababa were enrolled. Socio-demographic characteristics were obtained through 
a structured questionnaire and three to four ml of blood was collected from each 
child. ELISA was performed to determine antibody levels against HBV. The aver-
age age is seven + one (SD) years. Anti-HBs were detected in 54.3% (208/450) of 
children, and girls 98 (54.7%) had a slightly higher level of protection than boys 110 
did (53.9%). The overall coverage rate of the vaccine in this study was 85.1%. The 
proportion of children with protective levels (> 10 mIU / ml of anti-HBs antibod-
ies) decreased with increasing age of the children: 5, 6, 7 and 8 years were 52.6%, 
60%, 43.5% and 37.1%, respectively. The seroprevalence rate for HBsAg is 0.4% 
and the seroprevalence rate for anti-HBc is 5.6%. Age and antibody response level 
were negatively correlated (p = 0.001), while gender and history of HBV infection 
were not significantly correlated. Age was also significantly correlated with anti-
HBc seropositivity (p = 0.003). HBV vaccine coverage for children is high, but the 
antibody response to the vaccine appears to be low. The seropositivity rate for the 
virus is also very low. Low levels of response to the vaccine should be a problem. For 
unresponsive children, revaccination or booster doses should be considered. More 
research needs to be done.
Keywords: HBV, antibody response level, vaccination status, HBsAg, Anti HBsAg, 
Anti HBc
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1. Introduction
Hepatitis B virus (HBV) infection is a serious global health concern. Around two 
billion people have been infected with HBV worldwide, and more than 257 million 
people are currently living with hepatitis B virus infection [1]. There are an estimated 
600,000 deaths annually from complications of HBV-related liver diseases [2]. The 
highest numbers of HBsAg carriers are found in developing countries with limited 
medical facilities. Endemicity levels of chronic HBV infection are classified as high 
(>8%), intermediate (2-8%), or low (<2%). Based on this classification, sub-Saharan 
African countries including Ethiopia are considered regions of high endemicity [1].
HBV infection can be prevented by using the HBV vaccine. HBV vaccine has 
been commercially avail- able since the 1980s. In 1991, WHO recommended the 
integration of the HBV vaccine into the national immunization programs and by 
the end of 2005, the vaccine coverage was 82.3% globally [3, 4]. Hepatitis B vaccine 
for infants had been introduced in 183 countries by the end of 2013. In 2007, almost 
all sub-Saharan African countries had Hepatitis B vaccination in their national 
program [5]. HBV vaccine was introduced into the Ethiopian Expanded Program of 
Immunization (EPI) in 2007 and national coverage had reached 86% by 2015 [6].
Immune response to the vaccine can be determined by measuring the concentra-
tion of antibodies against the HBsAg. Anti-HBs in vaccinated children decline with 
time, especially during the first few years of vaccination. Most children produce a 
high concentration of antibodies following vaccination; however, few children can 
have low or no response to the vaccine. The reason for this low or no response against 
the HBV vaccine is not well known. However, the site of injection and modes of 
administration are thought to be critical factors in achieving an optimal response [7]. 
Data on the level of immune responses against HBV vaccine in Ethiopia is very lim-
ited. This study was conducted to contribute to the base- line data needed for further 
monitoring of HBV vaccination effectiveness in Ethiopia and provides information on 
the level of immune responses against HBV vaccine among children in Addis Ababa.
2. Patients and methods
2.1 Study area and period
The study was conducted in Addis Ababa, which is the capital city of Ethiopia 
from April 2016 to May 2017. A total number of 450 children (5-8 years old) were 
recruited.
2.2 Study design
A prospective cross-sectional study design was used. Healthy appearing 
5-8 years old children were included in the study following their parents’ consent. 
Vaccination status was used to include and exclude participants.
2.3 Sample size determination and sampling technique
The required samples size for this study was calculated using 50% of prevalence 
in vaccine response using the following formula:
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where, n = sample size
q = 1 – p
p = proportion
Z = confidence interval.
Using confidence interval of 95%, Z = 1.96
 
( )
( )
2
2
1.96 0.5 0.5
N 385
0.5
∗ ∗
= =  (2)
The total number of the samples with 10% non- respondents should come to 
424. However, just to be safe we collected 450 samples.
2.4 Data collection
There was a structured questionnaire to collect all relevant information about 
the study participants. After the participant’s family agreed to take part in the 
study, they signed an in- formed consent form. 3-4 ml of blood sample was 
collected from each child and the serum was separated and stored at -20°C until 
further use.
2.5 Ethical clearance
Ethical clearance was obtained from the AHRI/ALERT Research Ethics Review 
Committee and the department of ethical research committee. A support letter was 
obtained from the Addis Ababa Health Bureau and from the health bureaus of each 
sub city. Written informed consent was obtained from each participant’s parent or 
guardian before enrollment.
2.6 Data analysis and interpretation
SPSS Software statistical package version 20.0 was used to analyze the data. 
Association was determined by Chi-square test. P-values less than 0.05 were consid-
ered as statistically significant.
2.7 Serological assays
Serum level HBsAg, anti-HBc, and anti-HBsAg were determined using sandwich 
ELISA, where antigens/monoclonal antibodies were used both for capture and 
detection. All ELISA experiments were performed using BIO-RAD, Monolisa ELISA 
test kits, France. The test kits have a high sensitivity and specificity and each test 
procedure was undertaken according to the manufacturer’s instruction based on 
standard operating procedures.
2.8 Operational definitions
Hepatitis B virus: A DNA virus that attacks the liver and can cause both acute 
and chronic disease.
HBsAg: It is the surface antigen of the hepatitis B virus. It indicates the presence 
of active hepatitis B infection.
Anti-HBsAg: An antibody that is produced against HBV infection or 
vaccination.
Hepatitis B
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Anti-HBsAg: An antibody that indicates previous or ongoing infection with the 
hepatitis B virus in an undefined period.
3. Results
3.1 Socio-demographic characteristics
The mean age of the study participants was 7 ± 1 (SD) years. Among these, 
244 (54.2%) were male and 383 (85.1%) had been vaccinated. Forty-nine (10.9%) 
children had a history of infectious disease, fifteen (3.3%) had a history of nonin-
fectious disease, while three (0.7%) were HIV positive (Table 1).
Vaccination status Sex
Male Female Total P value
Frequency % Frequency %
Vaccinated 204 83.6 179 86.9 383 0.33
Non-vaccinated 40 16.4 27 13.1 67
Total 244 100 306 100 450
Table 2. 
The coverage of hepatitis B vaccination among 5-8 year-old children in Addis Ababa.
Characteristics Categories Number (n) Percentage
Sex Male 204 54.2
Female 206 45.8
Age 5 95 21.1
6 130 28.9
7 124 27.6
8 101 22.4
Place of birth Urban 422 93.8
Rural 28 6.2
Sub city Gulele 45 10
Kirkos 92 20.4
Lideta 313 69.5
History of previous disease status Yes 66 14.7
No 384 85.3
Infectious 49 10.9
Disease type Non Infectious 15 3.3
Immunocompromised 3 0.7
None 383 85.1
Vaccination status Vaccinated for HBV 383 85.1
Non vaccinated for HBV 67 14.9
Table 1. 
Socio demographic characteristics of children between the age of 5 and 8 years old in Addis Ababa Ethiopia.
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3.2 Vaccination status
383 (85.1%) out of 450 children had received HBV vaccination, of which 99.2% 
(380/383) of them had received the complete three doses of the vaccination. Only 
two (0.8%) children among the vaccinated had taken just two doses of the vaccine. 
There was no one who took only a single dose of the vaccine. The proportion of girls 
vaccinated (86.9%) is slightly higher than of boys (83.6%) as tabulated in Table 2.
3.3 Level of anti HBsAg Ab
Anti-HBsAg concentration > 10mIU/ml was observed in 214 (47.6%) children, 
six of whom were unvaccinated. Among the 383 vaccinated children, 208 (54.3%) 
had a protective level of antibody concentration (anti-HBsAg concentration of 
>10mIU/ml), while the remaining 47.3% did not. Among 67 unvaccinated children, 
61 (91%) had anti HBsAg <10mIU/ml. From the three HIV infected participants, 
two of them were vaccinated. However, they did not have protective level antibody 
response (anti-HBsAg <10mIU/ml) (Figure 1).
Figure 1. 
Antibody response against hepatitis B vaccine in children between 5 and 8 years, Addis Ababa Ethiopia.
Variables Categories Number (n) Percent (%) P value
Sex Male 15(244) 6.1 0.551
Female 10(196) 4.9
Vaccination status Vaccinated 10(383) 2.6 0.000
Not vaccinated 15(67) 22.4
Age 5 4(95) 4.2 0.03
6 3(130) 2.3
7 5(124) 4.0
8 13(101) 12.9
Previous disease status Yes 5(66) 7.6 0.438
No 20(384) 5.2
Table 3. 
Seroprevalence of anti-HBc in 5-8 years old children in Addis Ababa, 2016-2017.
Hepatitis B
6
Anti-HBsAg concentration by age: A protective level antibody response against 
HBV vaccine was observed in 52.6%, 60%, 43.5% and 37.1% of children at the ages 
of 5, 6, 7, and 8, respectively. There was a significant association between age and 
the concentration of anti-HBsAg (p = 0.001). The levels of antibody concentration 
decreased as the age of the participant increased.
Seroprevalence of hepatitis B: From 450 children, only two (0.4%) were positive 
for HBsAg and 25 (5.6%) were positive for anti-HBc. 1 child (0.2%) was positive for 
both HBsAg and anti-HBc (Table 3). The two children who were positive for HBsAg 
were females, 5 years old, asymptomatic, and vaccinated for HBV.
Among anti-HBc positive children, 15 (6.1%) were male while 10 (4.9%) 
were female. There was no significant association between sex and anti-HBcAb 
(p = 0.551). Ten (2.6%) of anti-HBc positive children had received vaccination 
prior to this study. Among non-vaccinated children in this study, 15 (22.4%) were 
anti-HBc positive. There was a negative correlation between vaccination status and 
anti- HBc positivity (p = 0.000).
The seroprevalence of anti-HBc was 4.2%, 2.3%, 4% and 12.9% in 5, 6, 7 and 
8 year old children, respectively. Age was significantly associated with anti- HBc 
seroprevalence (p = 0.03).
4. Discussion
The primary goal of vaccination against HBV is to generate an effective antibody 
response against the virus. The efficacy of HBV vaccine has not been determined in 
Ethiopia since its introduction in 2007. HBV vaccine coverage rate observed (85.1%) 
in our study is comparable with the estimated (86%) national coverage reported 
in 2015 [6]. Evidence has shown that the immune response against the vaccine 
decreases with increasing age. Our study observed a similar association between age 
and immune response against HBV vaccine.
In this study, 54.3% of vaccinated children had protective antibody response, as 
well as was obtained with low seroprevalence of HBsAg and anti-HBc of 0.4% and 
5.6%, respectively. This result is comparable with a study conducted in Yemen and 
in Iran, where 54.8% and 56.3% of the children had protective antibody responses, 
respectively [8, 9].
However, in other areas, higher proportions of children were reported with 
protective level antibody responses in comparison to our study. Studies con- ducted 
in different areas of Iran observed that 78% of 5-10 years old children [10], 84% of 
5 to 7 years old children [11], and 87.6% of under 7 years old children [12] had a pro-
tective level antibody response against HBV. A study that was conducted in Spain 
also revealed that 85% of children at the age of seven had protective level antibody 
response to the vaccine [13]. The difference in these countries could be attributed to 
differences in dose, vaccine type, and vaccination route.
In contrast to our study, a lower proportion of children with protective level 
antibody responses were observed in other studies. For example, in a study con-
ducted in Egypt, 39.3% of the children (6-12 years old) had protective level anti-
body responses [14]. In addition, in different areas of Iran, only 47.9% of 10-11 year 
old children [15], 48% of 7 to 9 year old children [16], and 30% of the 8 months to 
15-year-old children [17] had between ages of 8 months and 15 years had protec-
tive level antibody responses against HBV vaccine. These differences may be due to 
sampling difference, type of vaccine, and different age for vaccine administration.
Seroprevalence of HBsAg among vaccinated children varies in different coun-
tries ranging from 0 to 2.5%. Seroprevalence of HBsAg was 1.8% in Yemen [8], 
0.13% in Nepal [18], 2.3% in Papua New Guinea [19], 0.77% in Eastern China [20], 
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2.5% in northwest China [21], while it was 0.4% in our study. This difference in 
seroprevalence of HBV infection could be attributed to the difference in vaccine 
coverage and difference in vaccination schedule.
In our study, seroprevalence of anti-HBc was 5.6%, which is lower than anti-
HBc seroprevalence observed in studies conducted in Gambia (17.7%) [22], China 
(14.1%) [21] and Iran (7.5%) [23]. These discrepancies in anti-HBc seroprevalence 
could be attributed to age difference, race, prevalence of HBV, and immune 
response level.
Nowadays, mutant hepatitis B viruses are spreading globally. Vaccination regime 
and vaccine type should also be considered when we administer the vaccine to the 
child. High seroprevalence of anti- HBc in vaccinated children may indicate the 
presence of an occult HBV infection, which is a concern for everyone that needs to 
be addressed [24].
4.1 Limitations of the study
Some children did not come with their vaccination card. Therefore, we had to 
use the words of their parents/guardians as evidence for vaccination, which is not 
always reliable. Other serological markers of active HBV infection, like HBeAg, 
were not examined in this study. Further, there was an unequal number of vacci-
nated and non-vaccinated children and the study design did not account for occult 
infections.
5. Conclusion and recommendation
The vaccine coverage observed in this study is similar to that of the national 
estimate in 2014. However, less than half of the children had a protective level of 
anti- body response against HBV vaccine. Further, a negative association between 
anti-HBsAg antibody concentration and age was observed. Serological markers for 
hepatitis B virus were low: 0.4% for HBsAg and 5.6% of anti-HBc.
Persistence of anti-HBs antibodies is necessary for the long-term protection 
against hepatitis B virus infection. Even if different factors can contribute to low 
antibody response against the vaccine, we need to follow up children after vac-
cination, in order to see the effect of the vaccine in producing the desired response 
over time.
Finally, further studies should be undertaken to determine the duration of 
antibody response against HBV vaccine that may help in which years the vaccine 
response becomes less and less. For those who did not respond to the vaccine, 
booster doses should be given to enhance immunological responses to the vaccine. 
This can be important to elevate the vaccine response. Follow up is needed for those 
children who are administered with booster doses to evaluate response against the 
vaccine in those children.
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